Gsk (GSK) Total Debt (2009 - 2026)
Gsk (GSK) posted quarterly Total Debt of -$26.0 billion for Q2 2026, up 6.19% year-over-year from -$24.5 billion in Q2 2025, and little changed quarter-over-quarter from -$26.0 billion in Q1 2026.
Gsk (GSK) Total Debt (2009 - 2026) Analysis & Trends
Gsk's Total Debt history runs 18 years deep, the most recent figure standing at -$26.0 billion for Q2 2026.
- In Q2 2026, Total Debt rose 6.19% year-over-year to -$26.0 billion; the TTM figure through Jun 2026 stood at -$26.0 billion (up 6.19% YoY), while the FY2025 annual figure was -$26.5 billion, down 222.64% from the prior year.
- Total Debt for Q2 2026 stood at -$26.0 billion, roughly flat from -$26.0 billion in the prior quarter.
- The five-year high for Total Debt was $22.4 billion in Q4 2023, with the low at -$30.5 billion in Q2 2022.
- The 5-year median for Total Debt is -$26.4 billion (2023), against an average of -$19.0 billion.
- The sharpest annual moves came in 2023 and 2025: Total Debt surged 169.68% in 2023, then tumbled 223.22% in 2025.
- Gsk's Total Debt stood at $8.3 billion in 2022, then soared by 169.68% to $22.4 billion in 2023, then declined by 2.98% to $21.7 billion in 2024, then sank by 223.22% to -$26.7 billion in 2025, then increased by 2.85% to -$26.0 billion in 2026.
- Business Quant data shows GSK's Total Debt at -$26.0 billion in Q2 2026, -$26.0 billion in Q1 2026, and -$26.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.96 Bn |
| Mar 31, 2026 | -26.01 Bn |
| Dec 31, 2025 | -26.73 Bn |
| Sep 30, 2025 | -27.58 Bn |
| Jun 30, 2025 | -27.68 Bn |
| Mar 31, 2025 | -28.12 Bn |
| Dec 31, 2024 | 21.69 Bn |
| Sep 30, 2024 | -25.03 Bn |
| Jun 30, 2024 | -24.76 Bn |
| Mar 31, 2024 | -26.81 Bn |
| Dec 31, 2023 | 22.36 Bn |
| Sep 30, 2023 | -27.21 Bn |
| Jun 30, 2023 | -26.07 Bn |
| Mar 31, 2023 | -27.06 Bn |
| Dec 31, 2022 | 8.29 Bn |
| Sep 30, 2022 | -30.27 Bn |
| Jun 30, 2022 | -30.55 Bn |
| Mar 31, 2022 | -14.52 Bn |
| Dec 31, 2021 | 11.75 Bn |
| Sep 30, 2021 | -35.54 Bn |